EXTON, Pa.--(BUSINESS WIRE)-- Adolor Corporation (NasdaqGM: ADLR) today announced that Michael R. Dougherty, President and Chief Executive Officer, will present at the Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011, at 1:45 P.M. Eastern Time. The conference is being held at the Boston Marriott Copley Place, Boston, Massachusetts.
Adolor’s presentation will be webcast live on the investor relations section of the Company’s website and will be archived for one week following the broadcast. To access the webcast, log onto the Company’s website at www.adolor.com and click on “Investor Insights,” then “Webcast.” Click on the link and follow the prompts for registration and access.
About Adolor
Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products.
Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.® Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. In collaboration with GSK, the Company launched ENTEREG in mid-2008.
The Company's research and development pipeline includes: ADL5945 and ADL7445, novel mu opioid receptor antagonists undergoing clinical development for chronic OIC; and several earlier-stage compounds under development for the management of pain and CNS disorders.
For more information, visit www.adolor.com.
CONTACT:
Adolor Corporation
Stephen W. Webster, 484-595-1500
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Research Science
MEDIA: